Barbara Duncan

Barbara Gayle Duncan currently works at Halozyme Therapeutics, Inc., as Independent Director from 2023, Atea Pharmaceuticals, Inc., as Independent Director from 2020, Ovid Therapeutics, Inc., as Independent Director from 2017, Halozyme, Inc., as Director from 2023, and Versanis Bio, Inc., as Non-Executive Director from 2022.
Ms. Duncan also formerly worked at Fusion Pharmaceuticals, Inc., as Chairman from 2020 to 2024, Immunomedics, Inc., as Independent Director from 2019 to 2020, DOV Pharmaceutical, Inc., as Chief Executive & Financial Officer, Director from 2007 to 2009, Edgemont Pharmaceuticals LLC, as Director, SBC Warburg Dillon Read Corporate Finance AG, as Director-Corporate Finance from 1994 to 1998, Innoviva, Inc., as Director from 2016 to 2018, Aevi Genomic Medicine, Inc., as Independent Director from 2015 to 2020, Adaptimmune Ltd., as Non-Executive Director, Jounce Therapeutics, Inc., as Independent Director from 2016 to 2023, ObsEva SA, as Independent Director from 2016 to 2021, Adaptimmune Therapeutics Plc, as Independent Non-Executive Director from 2016 to 2023, Lehman Brothers, Inc., as Vice President-Corporate Finance Division in 2001, PepsiCo, Inc., as International Auditor from 1989 to 1992, Intercept Pharmaceuticals, Inc., as Chief Financial Officer, Secretary & Treasurer from 2010 to 2016, and Deloitte & Touche LLP, as Senior Accountant from 1986 to 1989.
Ms. Duncan received her undergraduate degree in 1985 from Louisiana State University and Masters Business Admin degree in 1994 from The Wharton School of the University of Pennsylvania.